Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07489885

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Study Center, Birmingham, Alabama, United States

Loading trial locations.

About this study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
  • Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
  • Within normal ranges of laboratory assessments

Exclusion criteria

  • Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Treatment and study plan

D-2570 Tablet

Drug

Active Treatment

Placebo tablets

Drug

Identical Tablet

Primary outcomes

  1. Improvement in PASI-90

    Time frame: Assessment completed after 12 weeks of treatment/placebo

    Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

Study contacts

Contact information is provided by the study sponsor or research team.

Kathryn Stazzone

CONTACT

[email protected]

3025195966

Sponsors and collaborators

Lead sponsor

InventisBio Co., Ltd

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Acronym: N/Z

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 24, 2026
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.